Evidence map›Paper›PMID 35667778›Full record

ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2022

Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force.

Wija Oortwijn, Don Husereau, Julia Abelson, Edwine Barasa, Diana Dana Bayani, Vania Canuto Santos, Anthony Culyer, Karen Facey, David Grainger, Katharina Kieslich and 5 more

Abstract read
In one paragraph

Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Rethinking the role of health technology assessment: from gatekeeper to health system shaper.International journal of technology assessment in health care · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Deliberative process of health technology reassessment by health technology assessment agency in Korea.International journal of technology assessment in health care · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Deliberative processes in health technology assessment of medicines: the case of Spain.International journal of technology assessment in health care · 2023
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wija OortwijnDepartment for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: w.oortwijn@radboudumc.nl.
Don HusereauSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Julia AbelsonDepartment of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada.
Edwine BarasaHealth Economics Research Unit (HERU), KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Diana Dana BayaniHealth Intervention and Policy Evaluation Research (HIPER), Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Vania Canuto SantosDepartment of Management and Incorporation of Health Technology, Executive Secretariat of National Committee Health Technology Incorporation (CONITEC), Ministry of Health, Brasilia, Brazil.
Anthony CulyerCentre for Health Economics, University of York, York, United Kingdom.
Karen FaceyEvidence Based Health Policy Consultant, Drymen, Scotland.
David GraingerBiointelect, Sydney, Australia.
Katharina KieslichDepartment of Political Science, Centre for the Study of Contemporary Solidarity, University of Vienna, Vienna, Austria.
Daniel OllendorfCenter for the Evaluation of Value and Risk in Health (CEVR), Tufts University Medical Centre, Boston, MA, USA.
Andrés Pichon-RiviereInstitute for Clinical Effectiveness and Health Policy (IECS), University of Buenos Aires, Buenos Aires, Argentina.
Lars SandmanNational Centre for Priorities in Health, Linköping University, Linköping, Sweden.
Valentina StrammielloEuropean Patients' Forum, Brussels, Belgium.
Yot TeerawattananonHealth Intervention and Technology Assessment Programme (HITAP), Ministry of Health, Bangkok, Thailand.

Funding

Wellcome Trust 203077
6 · The paper itself

Abstract

objectivesDeliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR-The Professional Society for Health Economics and Outcomes Research initiated a joint Task Force to address this gap.

methodsThe joint Task Force consisted of 15 members with different backgrounds, perspectives, and expertise relevant to the field. It developed guidance and a checklist for deliberative processes for HTA. The guidance builds upon the few, existing initiatives in the field, as well as input from the HTA community following an established consultation plan. In addition, the guidance was subject to 2 rounds of peer review.

resultsA deliberative process for HTA consists of procedures, activities, and events that support the informed and critical examination of an issue and the weighing of arguments and evidence to guide a subsequent decision. Guidance and an accompanying checklist are provided for (i) developing the governance and structure of an HTA program and (ii) informing how the various stages of an HTA process might be managed using deliberation.

conclusionsThe guidance and the checklist contain a series of questions, grouped by 6 phases of a model deliberative process. They are offered as practical tools for those wishing to establish or improve deliberative processes for HTA that are fit for local contexts. The tools can also be used for independent scrutiny of deliberative processes.

Indexed as

Biomedical TechnologyTechnology Assessment, BiomedicalAdvisory CommitteesChecklistEconomics, MedicalHumansdeliberative processesguidancehealth technology assessmentparticipationstakeholders

Identifiers

PMID35667778
PMCPMC7613534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.